Page last updated: 2024-08-21

isoxazoles and Parkinson Disease

isoxazoles has been researched along with Parkinson Disease in 39 studies

Research

Studies (39)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (2.56)	18.7374
1990's	4 (10.26)	18.2507
2000's	15 (38.46)	29.6817
2010's	19 (48.72)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hashizume, T; Kaneko, S; Kusaka, H; Morise, S; Nakamura, M; Oki, M; Takenouchi, N; Tsuge, A; Wate, R	1
Asano, T; Hikawa, R; Takahashi, R; Uemura, MT; Yamakado, H	1
Bhattacharya, P; Borah, A; Chakrabarty, J; Dutta, A; Mazumder, MK; Paul, R; Phukan, BC	1
Agrawal, N; Mishra, P	1
Assenza, G; Di Pino, G; Pellegrino, G; Tombini, M	1
Arawaka, S; Fukushima, S; Kato, T; Koga, K; Koyama, S; Sasaki, A; Sato, H	1
Hara, H; Hashizume, T; Ishisaka, M; Shimazawa, M; Tsujii, S	1
Fukasaka, J; Hasegawa, K; Kanazawa, I; Kochi, K; Murata, M; Shimazu, R	1
Iwata, N; Kishi, T; Matsunaga, S	1
Murata, M	5
Araki, T; Kato, H; Kuroiwa, H; Yano, R; Yokoyama, H	1
Perry, CM; Yang, LP	2
Janszky, J	1
Asanuma, M; Diaz-Corrales, FJ; Kikkawa, Y; Kimoto, N; Miyazaki, I; Miyoshi, K; Murata, M; Takeshima, M	1
Arias-Carrión, O; Höglinger, GU; Rösler, TW	1
Anciones, B; Bermejo, PE; Ruiz-Huete, C	1
Iijima, M; Kobayashi, M; Osawa, M; Uchiyama, S	1
Bajpai, M; Banerjee, A; Gharat, LA; Gudi, GS; Gullapalli, S; Sangana, RR; Yadav, PS	1
Kamiyama, T; Kono, Y; Mitsumura, H; Mochio, S; Morita, M; Oka, H; Sengoku, R; Takagi, S	1
Kanemaru, A; Kojima, T; Tokashiki, S; Ueda, Y	1
Kohmoto, J; Kondo, T; Miwa, H; Nakanishi, I	1
Gluck, MR; Granson, H; Santana, LA; Yahr, MD	1
Zareba, G	1
Hasegawa, K; Kanazawa, I; Murata, M	1
Bermejo, PE	1
Miwa, H	1
Asanuma, M; Diaz-Corrales, FJ; Miyazaki, I; Miyoshi, K; Murata, M; Ogawa, N	1
Alessandria, A; Bonifati, V; Giustini, P; Meco, G	1
Ford, B; Greene, P; Lynch, T	1
Tavares, AR	1
Ballard, CG; Harrison, RW; McKeith, IG	1
Horiuchi, E; Kanazawa, I; Murata, M	1
Bennett, JP; Cruz, CJ; Ferrari, MB	1

Reviews

8 review(s) available for isoxazoles and Parkinson Disease

Article	Year
Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis. Journal of Alzheimer's disease : JAD, 2017, Volume: 56, Issue:4 Topics: Antioxidants; Antiparkinson Agents; Drug Therapy, Combination; Humans; Isoxazoles; Parkinson Disease; Randomized Controlled Trials as Topic; Zonisamide	2017
[Therapy of Parkinson's disease--up to date]. Rinsho shinkeigaku = Clinical neurology, 2008, Volume: 48, Issue:11 Topics: Anticonvulsants; Antiparkinson Agents; Carbazoles; Dopamine Agents; Dopamine Agonists; Drug Design; Genetic Therapy; Humans; Isoxazoles; Levodopa; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic; Substantia Nigra; Zonisamide	2008
[Pharmacologic treatment of Parkinson disease]. Brain and nerve = Shinkei kenkyu no shinpo, 2009, Volume: 61, Issue:4 Topics: Age of Onset; Antiparkinson Agents; Dopamine Agonists; Glutathione; Humans; Isoxazoles; Levodopa; Neuroprotective Agents; Parkinson Disease; Superoxide Dismutase; Zonisamide	2009
[Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogyaszati szemle, 2009, Nov-30, Volume: 62, Issue:11-12 Topics: Anticonvulsants; Bipolar Disorder; Calcium Channels, T-Type; Cholinergic Agents; Dopamine Agents; Dyskinesias; Epilepsy; Excitatory Amino Acid Agents; Feeding and Eating Disorders; GABA Agents; Humans; Isoxazoles; Migraine Disorders; Nerve Tissue Proteins; Nervous System Diseases; Neuroprotective Agents; Obesity; Parkinson Disease; Randomized Controlled Trials as Topic; Sodium Channels; Treatment Outcome; Voltage-Gated Sodium Channel beta-2 Subunit; Zonisamide	2009
[The discovery of an antiparkinsonian drug, zonisamide]. Rinsho shinkeigaku = Clinical neurology, 2010, Volume: 50, Issue:2 Topics: Animals; Anticonvulsants; Dopamine; Humans; Isoxazoles; Male; Middle Aged; Parkinson Disease; Rats; Zonisamide	2010
Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Current pharmaceutical design, 2004, Volume: 10, Issue:6 Topics: Animals; Anticonvulsants; Antiparkinson Agents; Biogenic Monoamines; Calcium Channels, T-Type; Humans; Isoxazoles; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome; Zonisamide	2004
Zonisamide: review of its use in epilepsy therapy. Drugs of today (Barcelona, Spain : 1998), 2005, Volume: 41, Issue:9 Topics: Animals; Anticonvulsants; Biological Availability; Child; Child, Preschool; Drug Interactions; Epilepsy; Half-Life; Humans; Infant; Isoxazoles; Migraine Disorders; Pain; Parkinson Disease; Randomized Controlled Trials as Topic; Tissue Distribution; Zonisamide	2005
Zonisamide for the treatment of Parkinson's disease. Expert review of neurotherapeutics, 2007, Volume: 7, Issue:9 Topics: Anticonvulsants; Antiparkinson Agents; Brain; Clinical Trials as Topic; Humans; Isoxazoles; Parkinson Disease; Treatment Outcome; Zonisamide	2007

Trials

4 trial(s) available for isoxazoles and Parkinson Disease

Article	Year
Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study. Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:10 Topics: Aged; Anticonvulsants; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Isoxazoles; Japan; Male; Middle Aged; Parkinson Disease; Treatment Outcome; Zonisamide	2015
Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology, 2007, Jan-02, Volume: 68, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Motor Skills; Parkinson Disease; Single-Blind Method; Zonisamide	2007
Zonisamide in patients with essential tremor and Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2007, Oct-31, Volume: 22, Issue:14 Topics: Anticonvulsants; Essential Tremor; Humans; Isoxazoles; Parkinson Disease; Zonisamide	2007
Zonisamide has beneficial effects on Parkinson's disease patients. Neuroscience research, 2001, Volume: 41, Issue:4 Topics: Aged; Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Isoxazoles; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Rats; Selegiline; Treatment Outcome; Zonisamide	2001

Other Studies

27 other study(ies) available for isoxazoles and Parkinson Disease

Article	Year
Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats. Neuroscience research, 2017, Volume: 122 Topics: Animals; Anticonvulsants; Corpus Striatum; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Gene Expression; Isoxazoles; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptor, Cannabinoid, CB1; Receptors, Dopamine D1; Receptors, Dopamine D2; Zonisamide	2017
Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity. Neuroscience research, 2017, Volume: 124 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Astrocytes; Brain; Dopamine; Exploratory Behavior; Homovanillic Acid; Isoxazoles; Locomotion; Male; Mice, Inbred C57BL; Monoamine Oxidase; Neurons; Parkinson Disease; Social Behavior; Zonisamide	2017
Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease. Medical hypotheses, 2018, Volume: 117 Topics: Humans; Inflammation; Isoxazoles; Levodopa; Ligands; Molecular Conformation; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidative Stress; Parkinson Disease; Phytochemicals; Phytotherapy; Reactive Oxygen Species; Terpenes; Zonisamide	2018
Synthesis, monoamine oxidase inhibitory activity and computational study of novel isoxazole derivatives as potential antiparkinson agents. Computational biology and chemistry, 2019, Volume: 79 Topics: Animals; Antiparkinson Agents; Computer Simulation; Dose-Response Relationship, Drug; Humans; Isoxazoles; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Parkinson Disease; Structure-Activity Relationship	2019
Zonisamide for seizures in Parkinson's disease with dementia. Seizure, 2013, Volume: 22, Issue:4 Topics: Aged; Anticonvulsants; Dementia; Humans; Isoxazoles; Male; Parkinson Disease; Seizures; Zonisamide	2013
Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease. PloS one, 2014, Volume: 9, Issue:2 Topics: alpha-Synuclein; Animals; Cell Count; Dependovirus; Disease Models, Animal; Dopaminergic Neurons; Isoxazoles; Male; Mice; Neuroprotective Agents; Parkinson Disease; Protein Aggregation, Pathological; Rats; Substantia Nigra; Time Factors; Zonisamide	2014
Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo. European journal of pharmacology, 2015, Jan-05, Volume: 746 Topics: Animals; Anticonvulsants; Antiparkinson Agents; Cell Death; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Endoplasmic Reticulum Stress; Half-Life; Humans; Isoxazoles; Male; Mice, Inbred C57BL; MPTP Poisoning; Neurons; Neuroprotective Agents; Parkinson Disease; Substantia Nigra; Thapsigargin; Tunicamycin; Zonisamide	2015
A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice. Journal of molecular neuroscience : MN, 2009, Volume: 39, Issue:1-2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Astrocytes; Corpus Striatum; Dopamine; Glial Fibrillary Acidic Protein; Homovanillic Acid; Isoxazoles; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neurons; Neuroprotective Agents; Parkinson Disease; Substantia Nigra; Tyrosine 3-Monooxygenase; Zonisamide	2009
Zonisamide: in Parkinson's disease. CNS drugs, 2009, Volume: 23, Issue:8 Topics: Animals; Antioxidants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Drug Interactions; Epilepsy; Humans; Isoxazoles; Parkinson Disease; Zonisamide	2009
Zonisamide in Parkinson's disease: profile report. Drugs & aging, 2010, Jan-01, Volume: 27, Issue:1 Topics: Antioxidants; Humans; Isoxazoles; Parkinson Disease; Treatment Outcome; Zonisamide	2010
Neuroprotective effects of zonisamide target astrocyte. Annals of neurology, 2010, Volume: 67, Issue:2 Topics: Animals; Antiparkinson Agents; Astrocytes; Basal Ganglia; Carbidopa; Cells, Cultured; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glial Fibrillary Acidic Protein; Glutathione; Isoxazoles; Male; Mice; Mice, Inbred ICR; Nerve Growth Factors; Neuroprotective Agents; Oxidopamine; Parkinson Disease; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Tyrosine 3-Monooxygenase; Zonisamide	2010
Zonisamide: aspects in neuroprotection. Experimental neurology, 2010, Volume: 224, Issue:2 Topics: Animals; Anticonvulsants; Antiparkinson Agents; Humans; Isoxazoles; Neurons; Neuroprotective Agents; Parkinson Disease; Zonisamide	2010
Zonisamide: a new drug for Parkinson's disease. Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46, Issue:4 Topics: Animals; Anticonvulsants; Antiparkinson Agents; Clinical Trials as Topic; Half-Life; Humans; Isoxazoles; Neuroprotective Agents; Parkinson Disease; Tissue Distribution; Zonisamide	2010
Zonisamide in managing impulse control disorders in Parkinson's disease. Journal of neurology, 2010, Volume: 257, Issue:10 Topics: Aged; Antioxidants; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Isoxazoles; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Retrospective Studies; Zonisamide	2010
Efficacy of zonisamide in a case of Parkinson's disease with intractable resting and re-emergent tremor. European journal of neurology, 2011, Volume: 18, Issue:4 Topics: Aged; Antiparkinson Agents; Electromyography; Female; Humans; Isoxazoles; Parkinson Disease; Rest; Secondary Prevention; Tremor; Zonisamide	2011
Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation. Bioorganic & medicinal chemistry letters, 2012, May-01, Volume: 22, Issue:9 Topics: Central Nervous System; Cyclic Nucleotide Phosphodiesterases, Type 7; Humans; Isoxazoles; Parkinson Disease; Pharmacokinetics; Phosphodiesterase Inhibitors; Pyrimidinones; Structure-Activity Relationship; Thiazoles	2012
Actigraphic study of tremor before and after treatment with zonisamide in patients with Parkinson's disease. Parkinsonism & related disorders, 2012, Volume: 18, Issue:7 Topics: Actigraphy; Anticonvulsants; Humans; Isoxazoles; Motor Activity; Parkinson Disease; Treatment Outcome; Tremor; Zonisamide	2012
Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease. Biochemical and biophysical research communications, 2012, Nov-23, Volume: 428, Issue:3 Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Gene Expression; Gene Expression Profiling; Isoxazoles; Levodopa; Male; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Zonisamide	2012
[Effect of zonisamide on resting tremor resistant to antiparkinsonian medication]. No to shinkei = Brain and nerve, 2003, Volume: 55, Issue:8 Topics: Aged; Aged, 80 and over; Anticonvulsants; Antiparkinson Agents; Humans; Isoxazoles; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor; Zonisamide	2003
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity. Journal of neural transmission (Vienna, Austria : 1996), 2004, Volume: 111, Issue:6 Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Isoxazoles; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Zonisamide	2004
Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neuroscience research, 2008, Volume: 60, Issue:1 Topics: alpha-Synuclein; Animals; Antioxidants; Biopterins; Cell-Free System; Cells, Cultured; Cytosol; Dopamine; Isoxazoles; Ketanserin; Lewy Bodies; Melanins; Mice; Neurons; Oxidative Stress; Parkinson Disease; Quinones; Ubiquitin-Protein Ligases; Zonisamide	2008
Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet (London, England), 1994, May-28, Volume: 343, Issue:8909 Topics: Aged; Antipsychotic Agents; Hallucinations; Humans; Isoxazoles; Levodopa; Parkinson Disease; Piperidines; Risperidone	1994
Risperidone in Parkinson's disease. Lancet (London, England), 1994, Sep-03, Volume: 344, Issue:8923 Topics: Antipsychotic Agents; Humans; Isoxazoles; Parkinson Disease; Piperidines; Psychotic Disorders; Risperidone	1994
Risperidone in Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 1995, Volume: 58, Issue:4 Topics: Antipsychotic Agents; Humans; Isoxazoles; Parkinson Disease; Piperidines; Risperidone	1995
Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet (London, England), 1995, Sep-09, Volume: 346, Issue:8976 Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Female; Humans; Isoxazoles; Lewy Bodies; Male; Middle Aged; Parkinson Disease; Piperidines; Risperidone	1995
Health news. The sleeper syndrome. Harvard health letter, 2001, Volume: 26, Issue:3 Topics: Alzheimer Disease; Cacao; Humans; Hygiene; Isoxazoles; Margarine; Nicotine; Parkinson Disease; Pyrrolidines; Superoxides	2001
GABA-mimetic drugs enhance apomorphine-induced contralateral turning in rats with unilateral nigrostriatal dopamine denervation: implications for the therapy of Parkinson's disease. Annals of neurology, 1987, Volume: 21, Issue:1 Topics: Alkynes; Aminocaproates; Animals; Antiparkinson Agents; Apomorphine; Drug Synergism; gamma-Aminobutyric Acid; Isoxazoles; Male; Motor Activity; Nicotinic Acids; Parkinson Disease; Rats; Rats, Inbred Strains	1987